Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Patricia Russo | F | 71 | 29 years | |
Caroline Litchfield | F | 55 | 34 years | |
James Matteucci | M | - | 21 years | |
Steven Graziano | M | - | 18 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Robert P. Luciano | M | - | 23 years | |
Kenneth Frazier | M | 69 | 30 years | |
Richard Kogan | M | 81 | 21 years | |
P. Vagelos | M | 94 | 19 years | |
Richard Clark | M | 77 | 6 years | |
Raymond Gilmartin | M | 82 | 2 years | |
Fred Hassan | M | 78 | 6 years | |
Jeffrey Stein | M | 69 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 6 years |
John Schmid | M | 61 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 9 years |
Brendan M. O'Leary | M | 52 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 5 years |
Karin Eastham | F | 74 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 6 years |
Brian Atwood | M | 71 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 6 years |
Thomas W. Fry | M | 79 | 3 years | |
Donald S. Brooks | M | 88 | - | |
Michael Powell | M | 69 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 5 years |
Wendy Yarno | F | 68 | 9 years | |
Thomas Shenk | M | 77 | 11 years | |
Risa Stack | M | 55 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 5 years |
Charles Kidder | M | 79 | 12 years | |
Marino Carol | F | - | 8 years | |
Theodore Schroeder | M | 69 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 4 years |
Joseph Romanelli | M | 50 | 19 years | |
David Gionco | M | 63 | 3 years | |
Ismail Kola | M | 67 | 4 years | |
Michael Morneau | M | 58 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 5 years |
Joseph M. Danis | M | - | 10 years | |
Larry G. Edwards | M | 52 | 15 years | |
Laura Sepp-Lorenzino | M | 63 | 15 years | |
Nina Kjellson | F | 49 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 6 years |
Natarajan Sethuraman | M | 62 | 10 years | |
Peter Wendell | M | 73 | 21 years | |
Richard Markham | M | 73 | 20 years | |
Steven Goldstone | M | 78 | 6 years | |
William Harrison | M | 80 | - | |
Charles H. Hill | M | 69 | 31 years | |
Alan Levin | M | 62 | 20 years | |
Paul Truex | M | 55 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 5 years |
Wendell Weeks | M | 64 | 16 years | |
Anne Tatlock | F | 84 | - | |
Rochelle Lazarus | F | 76 | 16 years | |
David Anstice | M | 75 | 5 years | |
M. Anthony Burns | M | 81 | 25 years | |
Matthew Onaitis | M | 53 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | - |
Eric Schadt | M | 59 | 8 years | |
Elizabeth Hamilton Seabury Wyatt | M | 76 | 20 years | |
Andrew Plump | M | 58 | - | |
Celia A. Colbert | F | 67 | - | |
Raymond C. Jordan | M | 70 | 17 years | |
Kathleen Metters | M | 66 | 13 years | |
Clark Golestani | M | 57 | 24 years | |
Anastasia Daifotis | M | - | - | |
Wei Tang | M | - | 15 years | |
Clinton Lewis | M | 57 | - | |
Robert Segal | M | 66 | - | |
Oscar Ferenczi | M | 60 | - | |
Yan Li | F | 50 | 4 years | |
Lisa Escudero | F | 62 | 18 years | |
David A. Esposito | M | 55 | 13 years | |
Juan Camilo Arjona Ferreira | M | 54 | 12 years | |
Albert Lustig | M | - | - | |
Ernesto Aycardi | M | 61 | 11 years | |
Zane Yang | M | - | 3 years | |
Daniel Pascheles | M | - | 11 years | |
Jens Renstrup | M | 59 | 8 years | |
Mirian Graddick-Weir | M | 69 | 12 years | |
Christine Cioffe | F | - | 20 years | |
Silvana Battaglia | F | 56 | 10 years | |
Barry A. Polisky | M | 78 | 1 years | |
Dorothy P. Bowers | F | - | - | |
Mark E. McDonough | M | 59 | - | |
Abraham E. Cohen | M | 87 | 10 years | |
Michael Tarnow | M | 79 | 22 years | |
Robert F. Hendrickson | M | 91 | 5 years | |
Johnnetta Betsch Cole | M | 87 | 15 years | |
Kevin Koch | M | 63 | 7 years | |
Margaret McGlynn | F | 64 | 11 years | |
David Mauro | M | 59 | 7 years | |
Vijay Samant | M | 77 | 23 years | |
Jeffrey A. Peris | M | 77 | 25 years | |
Michael Atieh | M | 70 | 19 years | |
Laurie Olson | F | 61 | 32 years | |
Timothy Proctor | M | 74 | 13 years | |
Ryan Richard Paugh | M | - | - | |
Gene Clapp | M | - | - | |
Guy MacDonald | M | 65 | 22 years | |
Nolan Sigal | M | 73 | 10 years | |
Peter G. Ernster | M | 82 | 26 years | |
Thomas J. Ouellette | M | - | 16 years | |
J. Carroll | M | 74 | 25 years | |
John Canan | M | 67 | 8 years | |
Warren R. Winter | M | - | 15 years | |
Bharatt Chowrira | M | 59 | 1 years | |
Robert van Schoick | M | 73 | 28 years | |
Paul S. Miller | M | 65 | 24 years | |
Bradley Sheares | M | 67 | 19 years | |
Jacks Lee | M | 60 | - |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Kenneth Bartizal
- Personal Network